BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CPC Scientific - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CPC Scientific
X-ORIGINAL-URL:https://test.cpcscientific.com
X-WR-CALDESC:Events for CPC Scientific
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20240314T120000
DTEND;TZID=Europe/London:20240314T120000
DTSTAMP:20260521T024210
CREATED:20240313T045027Z
LAST-MODIFIED:20240313T061505Z
UID:10000043-1710417600-1710417600@test.cpcscientific.com
SUMMARY:PRRT Manufacturing  Case Study Presentation at Biologics 2024
DESCRIPTION:Join Andrew Kennedy\, Ph.D.Director of Business Development – Europe for his presentation on the optimization and manufacturing process of DOTAGA-Labeled Urea-Based Peptide PSMA Inhibitor. \nPeptide receptor radionuclide therapy (PRRT) is a targeted therapeutic strategy that uses peptides to deliver cytotoxic radiation levels to specific receptors overexpressed in cancer cells. Peptides are advantageous as therapeutic vectors in PRRT due to their small size\, favorable pharmacokinetics\, high binding affinity\, low immunogenicity and toxicity\, and minimal off-target binding. Tumor-targeting peptides conjugated to a radionuclide chelate constitute a new and powerful class of cancer medicines. Somatostatin\, cytokine (e.g.\, IL-13Ra2)\, and integrins receptors\, as well as vascular endothelial growth factor (VEGF)\, programmed death-ligand 1 (PD-L1)\, and prostate-specific membrane antigen (PSMA)\, have emerged as key targets for peptide radionuclide therapeutics. PSMA is an attractive target for prostate cancer because it’s overexpressed 100- to 1000-fold higher compared to normal tissue\, is present during all stages of the disease\, and its transmembrane conformation enables internalization of the therapeutic. This case study presents a manufacturing process for DOTAGA-Labeled urea-based peptide PSMA inhibitor API\, DOTAGA-(I-y)fk(Sub-KuE). In only ten months\, process development and GMP manufacturing were accomplished on a multigram scale. Process and analytical method development were carried out concurrently in the first three months\, followed by a pilot batch (13g\, one month)\, a toxicology study batch (29g\, one month)\, and GMP production (45g\, two months). Optimization of the synthesis\, cleavage\, and purification steps ensures a high crude yield (85-90% purity) and an overall yield of > 65% (> 98% purity). Developing an effective\, validated HPLC method to remove chiral isomer impurities affords easy resolution and isolation of the final product. \nAppointment Request\nWe would love to meet with you to discuss your peptide or oligonucleotide API project. Please visit us at Booth #53! or request to schedule an appointment using the form below. \nName*FirstLastEmail address*Phone Number*Company Name*Country*Please selectUnited StatesAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia And HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo\, The Democratic Republic Of TheCook IslandsCosta RicaCote D'IvoireCroatia (Local Name: Hrvatska)CubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrance\, MetropolitanFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard And Mc Donald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran (Islamic Republic Of)IraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKorea\, Democratic People's Republic OfKorea\, Republic OfKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacauMacedonia\, Former Yugoslav Republic OfMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia\, Federated States OfMoldova\, Republic OfMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint Kitts And NevisSaint LuciaSaint Vincent And The GrenadinesSamoaSan MarinoSao Tome And PrincipeSaudi ArabiaSenegalSeychellesSierra LeoneSingaporeSlovakia (Slovak Republic)SloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia\, South Sandwich IslandsSpainSri LankaSt. HelenaSt. Pierre And MiquelonSudanSurinameSvalbard And Jan Mayen IslandsSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania\, United Republic OfThailandTogoTokelauTongaTrinidad And TobagoTunisiaTurkeyTurkmenistanTurks And Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands (British)Virgin Islands (U.S.)Wallis And Futuna IslandsWestern SaharaYemenYugoslaviaZambiaZimbabweState*Please selectAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict Of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingState or Province*CPC Scientific is committed to protecting and respecting your privacy\, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time\, we would like to contact you about our products and services\, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose\, please tick below to say how you would like us to contact you: I agree to receive communications from CPC Scientific.SUBMIT
URL:https://test.cpcscientific.com/event/peptide-receptor-radionuclide-therapeutic-prrt-manufacturing-case-study-presentation-at-biologics-2024/
LOCATION:Novotel London West\, 1 Shortlands Hammersmith International Ctre\, London\, W6 8DR\, United Kingdom
CATEGORIES:Exhibitions,Presentations
ATTACH;FMTTYPE=image/png:https://test.cpcscientific.com/wp-content/uploads/2024/03/Biologics-Case-Study_thumbnail-min.png
END:VEVENT
END:VCALENDAR